This Research Topic is the second volume in this series, "Community Series in Novel Insights into Immunotherapy Targeting Tumor Microenvironment in Ovarian Cancer". Please see volume I
here.
Ovarian cancer (OC) is one of the most lethal gynecologic malignancies and seriously affects the health of women worldwide. Patients with OC often succumb to recurrence and resistance after the initial surgery and chemotherapy treatment. Thus, novel and effective treatment strategies are badly in need for ovarian cancer.
A recent landmark achievement in anti-cancer therapeutics is the clinical application of immunotherapy, which includes cancer vaccines, engineered immune cells such as TCR T cell and CAR T cell therapy, and immune checkpoint inhibitors (ICIs) such as CTLA-4 and PD-1/PDL-1. However, there are still some patients who suffered from cancers that cannot benefit from immunotherapy. Immunotherapies in ovarian cancer are still being tested in clinical trials and the response remains modest. Compelling evidence suggests that the limited response can be improved by co-treatment through altering the immune-suppressive tumor microenvironment (TME). Hence, an in-depth evaluation of immunotherapies targeting the tumor-promoting soluble factors, exosomes, malignant stroma cells, and dysfunctional immune cells in the ovarian cancer microenvironment would be contributive to the development of cancer immunotherapies.
This topic is centered around all aspects of the immunotherapies targeting the tumor microenvironment of ovarian cancer, including but not limited to exosomes, cell metabolism, and stroma/immune cell function.
We aim to compile a collection of Original Research and Review articles. Submissions may focus on, but are not limited to, the following subtopics:
1. How immunotherapy alters the ovarian cancer tumor environment: cells and physiological characteristics.
2. Efficacy evaluation of multi-immunotherapy in ovarian cancer: from bench to bed.
3. Exosomes in the ovarian cancer microenvironment.
4. New molecular targets in ovarian cancer microenvironment: mechanism and efficacy.
5. Targeting drug delivery system for ovarian cancer microenvironment: improve the effects of immunotherapy.
6. Novel cancer immunotherapy insights mining from big data by interdisciplinary strategies: predict the immunotherapy response in ovarian cancer patients.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
